Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, View ORCID ProfileAhmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
doi: https://doi.org/10.1101/2021.11.20.21266229
Hossein Faramarzi
1Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
M.D.Amirhossein Sahebkar
2Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran E-mail address:
3Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Pharm.D., Ph.D.Ahmad Hosseinpour
4Shimi Teb Salamat Co., Shiraz, Iran. E-mail address:
M.Sc.Vahid Khaloo
5Ali Asghar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
M.D.Parisa Chamanpara
6Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
Ph.D.Mohammad Reza Heydari
7Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail address:
Pharm.D., Ph.D.Sajad Najafi
8Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail address:
Ph.D.Fatemeh Fotoohi Khankahdany
4Shimi Teb Salamat Co., Shiraz, Iran. E-mail address:
M.Sc.Ahmad Movahedpour
9Behbahan Faculty of Medical Sciences, Behbahan, Iran. E-mail address:
Ph.D.Article usage
Posted November 25, 2021.
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
medRxiv 2021.11.20.21266229; doi: https://doi.org/10.1101/2021.11.20.21266229
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
medRxiv 2021.11.20.21266229; doi: https://doi.org/10.1101/2021.11.20.21266229
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2298)
- Dermatology (202)
- Emergency Medicine (371)
- Epidemiology (11623)
- Forensic Medicine (10)
- Gastroenterology (683)
- Genetic and Genomic Medicine (3629)
- Geriatric Medicine (341)
- Health Economics (622)
- Health Informatics (2332)
- Health Policy (919)
- Hematology (336)
- HIV/AIDS (758)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3390)
- Nursing (193)
- Nutrition (512)
- Oncology (1777)
- Ophthalmology (526)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1013)
- Primary Care Research (410)
- Public and Global Health (6021)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)